About dostarlima b
PD-1 immune checkpoint inhibitor
Used for
- Treats certain advanced or recurrent endometrial cancers, sometimes with chemotherapy.
- May be used alone or with chemotherapy, depending on cancer type and treatment setting.
Usual adult dose
500 mg by intravenous infusion every 3 weeks for 4 doses, then 1,000 mg every 6 weeks; regimen may vary by indication.
Common side effects
- Fatigue
- Nausea or diarrhoea
- Rash or itching
- Immune-related inflammation affecting organs such as lungs, bowel, liver, or thyroid
Important warnings
- Immune reactions can be severe or life-threatening and may occur during or after treatment.
- Report new breathing problems, persistent diarrhoea, jaundice, severe rash, or unusual weakness promptly.
- Treatment should be supervised by an oncology team.
- May cause complications in stem-cell transplantation after treatment.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for 4 months afterward.
Breastfeeding
Do not breastfeed during treatment or for 4 months after the last dose.
Interactions
- Tell the oncology team about all medicines, especially immune-suppressing treatments.
- Prior or planned stem-cell transplantation can increase the risk of serious complications.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.